Cargando…
COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases
Although most autoimmune diseases are considered to be CD4 T cell‐ or antibody‐mediated, many respond to CD20‐depleting antibodies that have limited influence on CD4 and plasma cells. This includes rituximab, oblinutuzumab and ofatumumab that are used in cancer, rheumatoid arthritis and off‐label in...
Autores principales: | Baker, D., Roberts, C. A. K., Pryce, G., Kang, A. S., Marta, M., Reyes, S., Schmierer, K., Giovannoni, G., Amor, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7405500/ https://www.ncbi.nlm.nih.gov/pubmed/32671831 http://dx.doi.org/10.1111/cei.13495 |
Ejemplares similares
-
Innate immunity during SARS‐CoV‐2: evasion strategies and activation trigger hypoxia and vascular damage
por: Amor, S., et al.
Publicado: (2020) -
Double-Positive Anti–Glomerular Basement Membrane Antibody and Myeloperoxidase Antineutrophil Cytoplasmic Autoantibody–Associated Glomerulonephritis Post COVID-19 mRNA vaccine: A Case Series of 4 Patients
por: Ting, Julie Anne, et al.
Publicado: (2023) -
Acute Tubulointerstitial Nephritis in a Patient on Anti-Programmed
Death-Ligand 1 Triggered by COVID-19: A Case Report
por: Buyansky, Dimitry, et al.
Publicado: (2021) -
Acute Kidney Injury and Renal Replacement Therapy in COVID-19 Versus Other Respiratory Viruses: A Systematic Review and Meta-Analysis
por: Cau, A., et al.
Publicado: (2021) -
Humoral and Cellular Immune Responses to SARS–CoV‐2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion
por: Simon, David, et al.
Publicado: (2021)